

Research Letter

## **SEROPREVALENCE AND CLINICAL SPECTRUM OF SARS-CoV-2 INFECTION IN THE FIRST VERSUS THIRD TRIMESTER OF PREGNANCY**

Francesca Crovetto, MD, PhD<sup>1</sup>, Fàtima Crispi, MD, PhD<sup>1</sup>, Elisa Llurba, MD, PhD<sup>2,3</sup>, Francesc Figueras, MD, PhD<sup>1</sup>, María Dolores Gómez-Roig, MD, PhD<sup>1,3</sup>, Eduard Gratacós, MD, PhD<sup>1\*</sup>.

<sup>1</sup>BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Sant Joan de Déu and Hospital Clínic), Institut de Recerca Sant Joan de Déu, IDIBAPS, Universitat de Barcelona, Center for Biomedical Network Research on Rare Diseases, Barcelona, Spain.

<sup>2</sup>Obstetrics and Gynaecology Department, Sant Pau University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

<sup>3</sup>Maternal and Child Health and Development Network (SAMID), RD16/0022/0015, Instituto de Salud Carlos III, Spain.

**Word count:** 585

**\*Corresponding author:** Eduard Gratacós, Head and Professor, BCNatal (Hospital Sant Joan de Déu and Hospital Clínic), Universitat de Barcelona, Passeig de Sant Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain. E-mail: [egratacos@sjdhospitalbarcelona.org](mailto:egratacos@sjdhospitalbarcelona.org)

### **Introduction**

Case registries of pregnant women diagnosed with coronavirus disease (COVID-19) by polymerase chain reaction (PCR) have reported that the majority experienced mild infection, but up to 9% may require critical care.<sup>1</sup> Most COVID-19 cases published were in the third trimester of pregnancy, which could reflect reporting bias, higher risk of infection or increased disease severity in late pregnancy.<sup>2</sup> Seroprevalence studies may allow reliable estimates of the susceptibility to infection and clinical spectrum since they include asymptomatic and mild infections not tested for PCR. We evaluated the seroprevalence and clinical presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnant women in the first and third trimester.

### **Methods**

The study was approved by the Institutional Review Board at each institution and informed consent was obtained. We recruited 874 consecutive pregnancies attending for first trimester screening (10-16 weeks' gestation, n=372) or delivery (n=502) from April 14 to May 5. All women were interviewed with a structured questionnaire for COVID-19 symptoms two months prior to sampling. SARS-CoV-2 IgG and IgM/IgA antibodies were tested (COVID-19 VIRCLIA® Monotest, Vircell Microbiologist, Spain; reported sensitivity 70% IgG and 89% IgM/IgA, and specificity 89% and 99% respectively). Indeterminate results were re-tested (VITROS® Immunodiagnostic Products Anti-SARS-CoV2 Total Tests, Ortho Clinical Diagnostics, USA; 100% sensitivity and specificity) and re-classified as positive or negative. Women with COVID-19 were diagnosed and managed according to standard protocols and guidelines<sup>3,4</sup>. Statistical differences were tested using the  $\chi^2$  test or Student t-test as appropriate (p<0.05).

## Results

A total of 125 of 874 women (14.3%) were positive for either IgG or IgM/IgA SARS-CoV-2 antibodies, 54/372 (14.5%) in the first and 71/502 (14.1%) in the third trimester. A total of 75/125 (60%) reported no symptoms of COVID-19 in the past 2 months, whereas 44 (35.2%) reported one or more symptoms, of which 31 (24.8%) had at least 3 symptoms or anosmia and 8 (6.4%) dyspnea. Overall, 7 women (5.6%) were admitted for persistent fever ( $>38^{\circ}$ ) despite paracetamol and dyspnea, of which 3 had signs of pneumonia on chest radiography. All 3 had criteria for severity (bilateral chest condensation, respiratory rate  $>30$  and leukopenia) and required oxygen support but not critical care or mechanical ventilation, and they were all discharged well. The rates of symptomatic infection, hospital admission or dyspnea were significantly higher in third trimester women (Table and Figure).

## Discussion

The 14.3% seroprevalence of SARS-COV-2 in pregnant women in this study was substantially larger than the contemporary rates of PCR positive cases (0.78%) reported for women 20-40y in Barcelona.<sup>5</sup> The data confirm that COVID-19 is asymptomatic in the majority of pregnant women<sup>6</sup> and illustrate the value of seroprevalence studies to capture the high proportion of asymptomatic or mild infections. In this study, none of the 125 pregnant women with SARS-CoV-2 infection required critical care as compared to 9% reported in cases diagnosed with PCR.<sup>1</sup> However, the proportion of infections with symptoms or dyspnea was remarkably higher in the third trimester, and these results are in line with COVID-19 registries, reporting that 81% of hospitalized women were in late pregnancy or peripartum.<sup>1</sup>

These results provide reassuring information that, even in settings with a high prevalence, SARS-CoV-2 infection in pregnancy mostly presents with asymptomatic or mild clinical forms. The susceptibility to infection seemed to be the same in the first and the third trimesters of gestation. The data further suggest that, as with other respiratory viruses, COVID-19 could be more severe and require increased surveillance in late pregnancy. These findings should be confirmed and extended with larger consecutive prevalence studies in pregnancy.

**Funding:** This study was funded by the KidsCorona Child and Mother COVID-19 Open Data & Biobank Initiative, Hospital Sant Joan de Déu, and “LaCaixa” Foundation, Barcelona, Spain.

**Additional contributions:** We thank all the medical staff, residents, midwives and nurses of BCNatal (Hospitals Sant Joan de Déu and Clínic) and Hospital Sant Pau, especially Rosalia Pascal, MD, Marta Larroya, MD, Cristina Trilla, MD, Martí Cantallops, MD, Marta Camacho, MD, M. Carmen Medina, MD, Irene Casas, MD, Marta Tortajada, MD, Àlex Cahuana, MD, Patricia Muro, MD, Marta Valdés, MD, David Boada, MD and Anna Mundo, MD, for careful data collection; Angela Arranz, PhD, for her key role in the coordination of the nursing research team; Imma Mercade, PhD, Elena Casals, PhD, and Josefina Mora, PhD, for their contribution in the collection of first trimester samples; Jordi Yague, PhD, and M. Angeles Marcos, PhD, for supervising the antibodies analyses; and the Biobanks of Fundació Sant Joan de Déu, Clínic-IDIBAPS and Sant Pau for valuable management of samples. None of them received any compensation for their contribution.

## References

1. The UK Obstetric Surveillance System SARS-CoV-2 Infection in Pregnancy Collaborative Group. Characteristics and outcomes of pregnant women hospitalised with confirmed SARS-CoV-2 infection in the UK: a national cohort study using the UK Obstetric Surveillance System (UKOSS). medRxiv preprint doi: <https://doi.org/10.1101/2020.05.08.20089268>
2. Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. *Emerg Infect Dis* 2008;14:95–100.
3. López M, Gonce A, Meler E, et al. COVID-19 in pregnancy: a clinical management protocol and considerations for practice. *Fetal Diagn Therapy* 2020. <http://doi.org/10.1159/000508487>
4. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. *Am J Respir Crit Care Med*. 2019;200:E45–67.
5. [http://aquas.gencat.cat/ca/actualitat/ultimes-dades-coronavirus/mapa-per-municipis/index.html#googtrans\(ca|en\)](http://aquas.gencat.cat/ca/actualitat/ultimes-dades-coronavirus/mapa-per-municipis/index.html#googtrans(ca|en))
6. Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. Coronavirus disease 2019 among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. *Am J Obstet Gynecol* MFM 2020 Apr 9;X100118. <http://doi.org/10.1016/j.ajogmf.2020.100118>

**Table.** Baseline characteristics and clinical features of pregnant women positive for SARS-CoV-2 infection (N=125) in the first versus third trimester.

Characteristics	First Trimester	Third Trimester	p
	N=54	N=71	
Age (years)	33.7 (5.1)	31.8 (6.1)	0.062
White ethnicity	31 (57.4)	43 (60.6)	0.697
Body mass index (Kg/m <sup>2</sup> )	24.1 (6.2)	23.9 (4.3)	0.209
Smoking status	4 (7.4)	6 (8.5)	0.543
Medical history			
Chronic hypertension	1 (1.9)	2 (2.8)	0.602
Diabetes mellitus	1 (1.9)	0 (0)	0.432
Autoimmune disease	2 (3.7)	0 (0)	0.185
Respiratory disease	2 (3.7)	3 (4.2)	0.297
Nulliparous	34 (63)	36 (50.7)	0.095
Multiple pregnancy	2 (3.7)	1 (1.4)	0.398
Symptoms compatible with COVID-19 within last 2 months			
None	38 (70.4)	37 (52.1)	0.012
Fever	7 (13)	16 (22.5)	0.152
Dry cough	5 (9.3)	17 (23.9)	0.034
Dyspnea	0 (0)	8 (11.3)	0.010
Tiredness	5 (9.3)	4 (5.6)	0.307
Sore throat	6 (11.1)	3 (4.2)	0.116
Rash on skin, or discoloration of fingers/toes	0 (0)	0 (0)	NA
Diarrhea	4 (7.4)	5 (7)	0.575
Loss of taste or smell	7 (13)	16 (22.5)	0.152
At least 3 symptoms or anosmia	9 (16.7)	22 (31.0)	0.065
Fever, cough and dyspnea	0 (0)	8 (11.3)	0.010
Hospital admission for COVID-19 symptoms	0 (0)	7 (9.9)	0.019

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

Data are expressed as n (%) or mean (SD)

**Figure.** Clinical spectrum of SARS-CoV-2 infection in pregnant women in the first and third trimester.

